Narrative review conceptualizes CVD as systemic immune–metabolic–inflammatory disease
Review suggests immune and metabolic factors drive cardiovascular disease progression
This narrative review synthesizes evidence on cardiovascular disease as a systemic immune–metabolic–inflammatory condition.
Immune and metabolic factors actively drive heart disease progression, offering new ways to assess risk and tailor prevention strategies.
SGLT2i use linked to lower adherence and QOL in HF patients in cross-sectional MTAC study
Taking More Heart Pills May Actually Feel Better, Not Worse
A cross-sectional study of 78 heart failure patients in a Malaysian MTAC program found SGLT2i users had significantly lower adherence (p = 0…
Heart failure patients taking more heart medicines reported feeling better, not worse, in a new study from Malaysia.
Meta-analysis identifies risk factors for diabetic kidney disease in Asian patients with type 2 diabetes
High Blood Pressure Is A Major Kidney Killer For Asian Diabetics
A meta-analysis of 24 studies including 12,047 Asian patients with type 2 diabetes found that SBP, hypertension, HbA1c, WHR, FBG, UA, Cr, ag…
High blood pressure is a top kidney killer for Asian diabetics, making blood pressure control just as critical as managing sugar levels to p…
Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
Why Ozempic's Heart Benefits May Have Nothing to Do With Weight Loss
An observational study of 47,199 patients with baseline cardiovascular disease in a U.S.
A massive real-world study of over 47,000 heart patients suggests that semaglutide may protect the heart through direct biological effects —…
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…
Remote monitoring chatbot increased GDMT target dose achievement in recently discharged HFrEF patients compared to standard care
A Simple Chatbot After Heart Failure Hospitalization May Keep You Healthier and Out of the Hospital
This randomized controlled trial enrolled 66 patients with heart failure with reduced ejection fraction (HFrEF) recently discharged from the…
For people with heart failure, consistent digital check-ins after leaving the hospital could be the key to getting the right medication stre…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new pill for type 2 diabetes that also helps protect the heart
The FDA has approved dapagliflozin tablets for two indications in adults with type 2 diabetes mellitus: to improve glycemic control and to r…
A new FDA-approved pill for type 2 diabetes now helps lower blood sugar while also reducing the risk of hospitalization for heart failure.
Meta-analysis finds SGLT2 inhibitors reduce mortality and hospitalization in older heart failure patients
Older Adults With Heart Failure May Gain Years From This Pill
A systematic review and meta-analysis of 20,844 patients aged 65+ with heart failure found SGLT2 inhibitors were associated with reduced all…
A pooled look at 10 studies in over 20,000 older adults shows SGLT2 inhibitors cut the risk of dying from any cause by about a fifth — and t…
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart in certain adults
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug is approved to lower blood sugar and cut the risk of heart failure hospitalization in adults with type 2 diabetes and he…
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF
New drugs may lower heart failure risk and improve walking distance for patients with preserved ejection fraction
This network meta-analysis evaluated 48,235 patients with heart failure with preserved ejection fraction (HFpEF) treated with various pharma…
New heart drugs lower death risk and hospital visits for patients with preserved ejection fraction while improving walking distance.
Self-management and glycemic control linked to lower MCI risk in rural elderly with type 2 diabetes
Better diabetes self-care linked to lower cognitive decline risk in rural elderly study
A cohort study of 232 rural Chinese elderly with type 2 diabetes found improved self-management behaviors, fewer depressive symptoms, and be…
Better diabetes self-care and mood control in older adults with type 2 diabetes were linked to a lower risk of memory problems in a rural Ch…
Structured exercise program improves glycemic control and fitness in Bangladeshi adults with type 2 diabetes
Can six weeks of guided exercise help manage diabetes better than medication alone?
A 6-week RCT in 90 Bangladeshi adults with type 2 diabetes found that adding a physiotherapist-led exercise program to medication improved c…
Six weeks of guided exercise alongside medication improved blood sugar, walking distance, and quality of life for adults with type 2 diabete…